Selank

Also known as: TP-7, Selank acetate

Limited Evidence

Classification

Peptide

Regulatory Status

not-established

Overview

Selank is a synthetic heptapeptide tuftsin analog developed in Russia; proposed mechanisms include modulation of enkephalin-degrading enzymes. US clinical mechanism is not established by an FDA-approved label.

Evidence and limitations

Human/preclinical evidence breakdown is not available in this record.

Pathways

neuropeptide-signalingendogenous-opioid-modulation-proposedtuftsin-analog peptide signalingenkephalin-degrading-enzymes-proposed

enkephalin-degrading enzyme inhibition (proposed)

Interactions & cautions

Drug interactions

benzodiazepines or other CNS-active anxiolytics — Additive sedation or confounded response monitoring is possible but not established in an FDA interaction table. (review)

These are observational flags for review, not individualized instructions.

Sources

https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks (opens in a new tab)
https://pubmed.ncbi.nlm.nih.gov/18454096/ (opens in a new tab)
https://pubchem.ncbi.nlm.nih.gov/compound/Selank (opens in a new tab)

Educational reference only — not medical advice.